奥沙利铂联合替吉奥与奥沙利铂联合卡培他滨治疗胃癌的有效性及安全性研究

Efficacy and Safety of Oxaliplatin Combined with Tegafur and Oxaliplatin Combined with Capecitabine in the Treatment of Gastric Cancer

目的:探究奥沙利铂联合替吉奥与奥沙利铂联合卡培他滨治疗胃癌的有效性及安全性研究。方法:回顾性分析2018年1月至2021年6月景德镇市第二人民医院收治的60例胃癌患者的病历资料,根据不同治疗方式分为两组,XELOX组及SOX组,每组均为30例。XELOX组进行奥沙利铂联合卡培他滨治疗,SOX组进行奥沙利铂联合替吉奥治疗,比较两组患者治疗效果及安全性。结果:XELOX组治疗疾病控制率及客观缓解率分别为90.00%、60.00%,SOX组治疗疾病控制率、客观缓解率分别为93.33%、63.33%,组间比较差异无统计学意义(P>0.05);XELOX组与SOX组,肝功能异常发生率分别为10.00%、36.67%,血小板减少分别为6.67%、33.33%,SOX组高于XELOX组,手足综合征发生率分别为40.00%、10.00%,线粒体缺失发生率分别为36.67%、10.00%,XELOX组高于SOX组(P<0.05)。结论:胃癌患者采用奥沙利铂联合替吉奥与奥沙利铂联合卡培他滨化疗效果差异无统计学意义,均未发生严重不良反应,卡培他滨会增加手足综合征及线粒体缺失风险性,替吉奥会增加肝功能损害及血小板减少风险性,因此治疗前,需针对性了解患者耐受,选择合适化疗方案,以最大限度提升患者预后。

Objective:To investigate the efficacy and safety of oxaliplatin combined with tegafur and oxaliplatin combined with capecitabine in the treatment of gastric cancer.Methods:The medical records of 60 gastric cancer patients admitted to Second People’s Hospital of Jingdezhen from January 2018 to June 2021 were retrospectively analyzed,and they were divided into two groups according to different treatment methods,the XELOX group and the SOX group,each with 30 cases.The XELOX group was treated with oxaliplatin combined with capecitabine,and the SOX group was treated with oxaliplatin combined with tegafur.The therapeutic effect and safety of the two groups were compared.Results:The disease control rate and objective response rate in XELOX group were 90.00%and 60.00%respectively.The disease control rate and objective response rate in SOX group were 93.33%and 63.33%,respectively.There was no significant difference in the comparisons between the groups(P>0.05).In XELOX group and SOX group,the incidence of abnormal liver function was 10.00%and 36.67%,thrombocytopenia was 6.67%and 33.33%,respectively.SOX group was higher than XELOX group,the incidence of hand foot syndrome was 40.00%and 10.00%,and the incidence of mitochondrial loss was 36.67%and 10.00%,respectively.XELOX group was higher than SOX group(P<0.05).Conclusion:There was no significant difference in the effect of chemotherapy between oxaliplatin combined with tegafur and oxaliplatin combined with capecitabine.No serious adverse reactions have occurred,capecitabine increases the risk of hand-foot syndrome and mitochondrial loss and tegafur increases the risk of liver function impairment and thrombocytopenia.Therefore,before the treatment,it is necessary to specifically understand the patient tolerance and choose the appropriate chemotherapy regimen to maximize the patient prognosis.